Member of Technical Staff

OpenEvidence has launched a new family of medical AI models designed for clinical use. The models include Osler, which provides answers in approximately five seconds for bedside consultations; Sackett, a deeper search model taking around 30 seconds; and Snow, the most comprehensive production model requiring approximately five minutes to analyse medical literature. All three models are rolling out free to verified clinicians via the OpenEvidence website and mobile apps. The company also announced Darwin, described as the most advanced medical AI model globally, which achieved a perfect score on MedQA, the leading medical AI benchmark. Darwin is currently in research preview and available only by application due to dual-use concerns. OpenEvidence reports being the most popular AI platform amongst American physicians.

OpenEvidence deepens oncology push to build specialized AI agents, launches new AI model family. OpenEvidence is leveraging a partnership with a top cancer center to bolster its oncology capabilities, adding trusted genomic interpretation expertise to the AI platform already used by millions of clinicians. Through the partnership, the company will integrate a precision oncology knowledge base directly into its workflows for expanded use by providers. OpenEvidence previewed the partnership exclusively with Fierce Healthcare, referring to the partner as a "nationally leading cancer center," with plans to identify the organization next week. The partnership brings precision oncology decision support to clinicians nationwide and deepens OpenEvidence's push into cancer care as the company already directly integrates the foundational frameworks of cancer treatment into its medical search engine. The company has a licensing agreement with the National Comprehensive Cancer Network (NCCN), which integrates its evidence-based oncology guidelines into its platform. The company also integrates ASCO Guidelines, figures and flowcharts into its model. Through its latest partnership with a leading cancer center, OpenEvidence users gain access to expert-curated interpretations of cancer genomic alterations alongside patient-specific context and peer-reviewed evidence, helping clinicians make more informed treatment decisions, according to OpenEvidence executives. The partnership also builds on OpenEvidence's vision to develop "medical superintelligence" based on agentic artificial intelligence, or a system of AI agents that can be subspecialists in clinical areas, as OpenEvidence founder Daniel Nadler, Ph.D. detailed back in January at the 2026 J.P. Morgan Healthcare Conference. OpenEvidence has set its sights on building medical specialist AI models, starting with oncology. Just as neural networks digitally recreated the architecture of intelligence, "medical superintelligence" will digitally recreate groups of experts and specialists, "composing many subspecialty expert models to build a single, more powerful intelligent system acting as a full multispecialty care team that every physician can hold in their hand," Nadler told Fierce Healthcare. The company is now integrating a leading cancer center's precision oncology knowledge base directly into its specialized oncology sub-agent - an AI agent that has already officially digitized the NCCN treatment algorithms, Nadler noted. Nadler said the company has partnered with several nationally-leading cancer centers and those partnerships would be announced "in the coming weeks." "In the near future, we will be rolling out the next OpenEvidence specialist agents in genetics, cardiology and neurology. Our vision is that, in aggregate, this dynamic ensemble of medically specialized agents will not only transcend the limitations of any individual human expert but will also result in a seismic-scale equalization of healthcare quality in America. This will allow every rural or under-resourced county in the country - whose physicians historically had scarce access to sub-specialist knowledge - to carry in their white coat pocket a world-class multispecialty care team or tumor board, on-call 24/7 - for free," Nadler said. OpenEvidence developed an AI-powered medical search engine and a generative AI chatbot exclusively for doctors, which summarizes and simplifies evidence-based medical information. As of September, there were 1.12 million medical licensed-verified U.S. clinicians, including physicians, nurses, nurse practitioners and physician assistants, using OpenEvidence. August is tracking to over 40 million NPI-verified queries from U.S. clinicians in the last 30 days, Nadler told Fierce Healthcare. The company also released a new family of medical AI models, including OpenEvidence Darwin, what the company calls its most advanced medical AI model, which is now in research preview. According to OpenEvidence, Darwin is the first AI model in history to achieve a perfect score on MedQA, a fully-independent medical AI benchmark. The company also touted Darwin's performance on other leading benchmarks of medical AI: MedXpertQA (72.8%), HealthBench Professional (82.7%) and NOHARM (87.2%), ahead of the next-best models (Claude Fable 5 and Gemini 3.7). Darwin is available by application only, currently being used by institutional partners such as the National Organization for Rare Disorders (NORD), research collaborators and accredited AI researchers at academic institutions, the company said. "As Darwin's safeguards are validated with these partners, its capabilities will flow, model by model, into Osler, Sackett, and Snow - the frontier arriving at the point of care as fast as it can arrive safely," the company said. The company named the models after the founders of modern medicine. OpenEvidence said it built Osler (named for William Osler), what it calls its fastest model that provides answers in about five seconds, for the pace of point of care. Osler is the successor to the model that currently powers OpenEvidence answers, and will continue to be the default model on the platform, the company said. OpenEvidence Sackett (named for David Sackett) is a deeper search model for questions that turn on the weight of the evidence, according to the company, and Snow (named for John Snow) is OpenEvidence's deepest production model that runs a full investigation of world medical literature before providing a report. "Every model in the family is held to the same standard of clinical accuracy. What varies is time: how long a model thinks, and how deep it searches," the company said in a blog post. The company said the Osler, Sackett and Snow models are rolling out to all OpenEvidence users today - free to verified clinicians. In the past four years, OpenEvidence has expanded from clinical search into other clinical workflows, which puts it into more direct competition with players like Wolters Kluwer's UpToDate and Elsevier as well as Abridge and Doximity. In August, the company rolled out its Visits feature, a clinical AI assistant that transcribes patient visits. The company made an AI-integrated doctor dialer feature more widely available, directly taking on Doximity's core business. In March, it released an AI-powered medical coding feature that provides automatic Current Procedural Terminology (CPT) code suggestions and evaluation and management (E/M) level recommendations. In May, OpenEvidence rolled out a voice AI feature that gives physicians a hands-free way to ask questions and get evidence-based answers. The company said Voice Mode is a native speech-to-speech medical AI interface, calling it the first multimodal medical AI offering for clinical decision support. Let Google know we are your trusted source. Add our editorial as a preferred source in your search results.

Orthopaedic industry daily briefing | 2026-08-31. Curated for Orthogate.org Members Executive Summary. * Globus Medical Acquires Higgs Boson Health to Expand Digital Care and AI Platforms: Globus Medical acquired Duke-incubated digital health developer Higgs Boson Health to integrate AI-driven patient engagement, remote monitoring, and perioperative management into its musculoskeletal surgical ecosystem. * AMSSM and OpenEvidence Partner to Deliver AI Clinical Decision Support in Sports Medicine: The American Medical Society for Sports Medicine (AMSSM) entered a collaboration with OpenEvidence to co-develop specialized AI point-of-care clinical resources for sports medicine physicians. * Tenon Medical Prices $3M Private Placement to Accelerate Catamaran(R) SI Joint Fusion Commercialization: Tenon Medical secured $3.0 million in private equity financing to fund commercial distribution and clinical education for its Catamaran(R) SI Joint Fusion system. Corporate, M&A & digital health. Globus Medical - Acquires Higgs Boson Health to drive ai-powered episode-of-care solutions. * Summary: Globus Medical, Inc. (NYSE: GMED) announced the acquisition of Higgs Boson Health, a Durham, NC-based digital health company incubated out of Duke University. The acquisition expands Globus Medical's digital health suite, combining Higgs Boson's AI-enabled patient engagement and care management software with Globus's ExcelsiusGPS(R) robotic navigation ecosystem to optimize clinical workflows from preoperative planning through post-operative recovery. * Key Details: * Device/System Name: Higgs Boson Digital Care Platform & ExcelsiusGPS(R) Ecosystem * Status: Strategic M&A Completed * Clinical Significance: Connects intraoperative robotic surgical navigation with remote patient tracking and education, improving patient compliance and streamlining post-operative outcome reporting. * Original Source: Globus Medical Acquisition Announcement - GlobeNewswire Sports Medicine & Clinical AI. AMSSM & OpenEvidence - Strategic partnership to co-develop AI Sports Medicine Clinical Decision tools. * Summary: The American Medical Society for Sports Medicine (AMSSM) and OpenEvidence announced an exclusive partnership to develop specialized AI-driven clinical resources for sports medicine clinicians and athletes. The collaboration incorporates AMSSM's clinical guidelines, position statements, and expert-authored sports medicine content into OpenEvidence's clinical decision support search platform. * Key Details: * Device/System Name: AMSSM / OpenEvidence Sports Medicine Clinical AI Platform * Status: Strategic Educational & Clinical AI Partnership * Clinical Significance: Delivers rapid, evidence-grounded point-of-care guidance for clinicians evaluating acute musculoskeletal trauma, concussions, and return-to-play decisions. * Original Source: AMSSM & OpenEvidence Partnership Announcement - OrthoSpineNews Spine & sacro-pelvic reconstruction. Tenon Medical - announces pricing of $3M Private Placement offering for Catamaran(R) Expansion. * Summary: Tenon Medical, Inc. (NASDAQ: TNON) announced a securities purchase agreement for a $3.0 million private placement offering of common stock and accompanying warrants at an effective price of $5.02 per share. Net proceeds will fund nationwide commercial distribution, clinical trial evidence generation, and surgeon training for the Catamaran(R) Sacroiliac (SI) Joint Fusion System. * Key Details: * Device/System Name: Catamaran(R) SI Joint Fusion System * Status: Private Placement Financing ($3.0M) / Commercial Expansion * Clinical Significance: Supports expanded surgeon access and training for single-transfixion posterior-inferior sacroiliac joint stabilization in outpatient and ASC settings. * Original Source: Tenon Medical Private Placement Announcement - OrthoSpineNews Spinal Elements - Commercial Launch of Overwatch(R) PCF Posterior Cervical Fixation System. * Summary: Spinal Elements announced the commercial launch of Overwatch(R) PCF, a posterior cervical fixation system engineered for complex cervical and occipito-cervico-thoracic reconstruction. The system features polyaxial screws offering 120 degrees of angulation, freely functioning low-profile tulips, and self-selecting set screws designed to simplify rod seating in crowded posterior cervical anatomy. * Key Details: * Device/System Name: Overwatch(R) PCF Posterior Cervical Fixation System * Status: Commercial Launch / FDA 510(k) Cleared * Clinical Significance: Streamlines instrumentation and screw-rod assembly in multi-level posterior cervical fusions, reducing soft-tissue retraction strain and operative time. * Original Source: Spinal Elements Overwatch PCF Launch - SPINEMarketGroup NEW FDA 510(k) & PMA CLEARANCE LISTING (PAST 24-48 HOURS). | Company | Device / System Name | Indication / Specialty | K-Number / PMA ID | Direct Link | | Globus Medical | Higgs Boson Health Care Platform | Perioperative Care & Patient Engagement | M&A Acquisition | GlobeNewswire Release | | Spinal Elements, Inc. Overwatch(R) PCF Posterior Cervical System | Occipito-Cervico-Thoracic Posterior Fixation | K233140 | Launch Announcement | | Tenon Medical, Inc. Catamaran(R) SI Joint Fusion System | Sacroiliac Joint Fusion | K260955 | OrthoSpineNews Notice | - Last Updated: 02 September 2026